Zheng B Lin

US Patent:

8067201, Nov 29, 2011

Filed:

Apr 19, 2010

Appl. No.:

12/763168

Inventors:

Paul Morin - Pennington NJ, US
Zheng Lin - Princeton NJ, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C12P 21/06
C12N 9/00
C07K 1/00

US Classification:

435 691, 435183, 530402

Abstract:

Provided herein are methods for refolding proteins. The methods involve covalently modifying a denatured protein with a nonproteinaceous polymer and then renaturing the modified protein.

US Patent:

20190055321, Feb 21, 2019

Filed:

Aug 14, 2018

Appl. No.:

16/103654

Inventors:

- Princeton NJ, US
Yong Zhang - West Windsor NJ, US
Gregory D. Vite - Titusville NJ, US
Arvind Rajpal - San Francisco CA, US
Paul E. Morin - Pennington NJ, US
Mohan Srinivasan - Cupertino CA, US
Zheng Lin - North Wales PA, US
Virginie Lafont - Lawrence Township NJ, US
Alla Pritsker - Morganville NJ, US

International Classification:

C07K 16/46

Abstract:

A prodrugged antibody has a blocking moiety attached to a Cys on its heavy or light chain via a linker having a cleavable moiety. The blocking moiety inhibits binding of the antibody to its antigen. Cleavage of the cleavable moiety releases the blocking moiety and restores ability of the antibody to bind to its antigen.

US Patent:

20180038872, Feb 8, 2018

Filed:

Sep 29, 2017

Appl. No.:

15/720073

Inventors:

- Princeton NJ, US
Alexander T. Kozhich - Princeton NJ, US
Martin J. Corbett - Mount Holly NJ, US
Zheng Lin - North Wales PA, US
Steven P. Piccoli - Princeton NJ, US

International Classification:

G01N 33/68
C07K 16/44

Abstract:

Polyethylene glycol (PEG) is often conjugated with therapeutic proteins to enhance their PK properties. PEG may, however, be immunogenic, and the presence of PEG in food and cosmetics is believed to result in pre-existing anti-PEG antibodies in humans. Polyclonal and monoclonal antibodies reactive to PEG are provided for use in immunogenicity assay development to detect such anti-drug antibodies. Such antibodies exhibit preferential binding based on the size of PEG with molecular weight ranging from 350 daltons to 40 kD. Anti-PEG antibodies of the invention are engineered to comprise human Fc regions to enable non-bridging immunoassay formats.

US Patent:

20160231328, Aug 11, 2016

Filed:

Feb 8, 2016

Appl. No.:

15/018353

Inventors:

- Princeton NJ, US
Alexander T. Kozhich - Princeton NJ, US
Martin J. Corbett - Mount Holly NJ, US
Zheng Lin - North Wales PA, US
Steven P. Piccoli - Princeton NJ, US

International Classification:

G01N 33/68
C07K 16/44

Abstract:

Polyethylene glycol (PEG) is often conjugated with therapeutic proteins to enhance their PK properties. PEG may, however, be immunogenic, and the presence of PEG in food and cosmetics is believed to result in pre-existing anti-PEG antibodies in humans. Polyclonal and monoclonal antibodies reactive to PEG are provided for use in immunogenicity assay development to detect such anti-drug antibodies. Such antibodies exhibit preferential binding based on the size of PEG with molecular weight ranging from 350 daltons to 40 kD. Anti-PEG antibodies of the invention are engineered to comprise human Fc regions to enable non-bridging immunoassay formats.